newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious